Anti-Rho GTPase conformational single domain antibodies and uses thereof
US-10544210-B2 · Jan 28, 2020 · US
Anti-rho GTPase conformational single domain antibodies and uses thereof
US11319381B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11319381-B2 |
| Application number | US-201916703343-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 4, 2019 |
| Priority date | Feb 3, 2015 |
| Publication date | May 3, 2022 |
| Grant date | May 3, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibody which are defined in Table B.
First claim
Opening claim text (preview).
We claim: 1. A nucleic acid molecule which encodes a single domain antibody, wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the single domain antibody are set forth as SEQ ID NOS: 5-7. 2. A vector which includes the nucleic acid molecule of claim 1 . 3. A host cell transformed with the nucleic acid molecule of claim 1 .
Assignees
Inventors
Classifications
for enzymes or isoenzymes · CPC title
Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody® · CPC title
Framework region [FR] · CPC title
- C07K16/40Primary
against enzymes · CPC title
comprising antibodies · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11319381B2 cover?
- The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-…
- Who is the assignee on this patent?
- Inst Nat Sante Rech Med, Univ Toulouse 3 Paul Sabatier, Inst Claudius Regaud, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/40. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).